Survival of childhood leukemia in Singapore

Medical and Pediatric Oncology
T C QuahB W Lee

Abstract

The objective of this study was to evaluate the treatment outcome of children with acute leukemias at a university hospital in Singapore. Between January 1988 and January 1994, 66 children were treated, comprising 13 cases of acute myeloid leukemia (AML) and 53 acute lymphoblastic leukemia (ALL). The 2-year disease-free survival (DFS) was computed according to the Kaplan-Meier method. The results showed that the survival of AML was poor, with a 2-year DFS of only 30%. The major cause of death for AML was leukemia and leukemia-related complications, such as hemorrhage and severe infections. In contrast, a 62% 2-year DFS was achieved for ALL. It was found that marked hepatosplenomegaly (enlarged liver and/or spleen > or = 10 cm below the costal margin) at presentation correlated with a significance shortened survival in our patients with ALL. The major cause for treatment failure in ALL was recurrence of disease. We conclude that the DFS for our patients with ALL at 2 years was fair. The treatment results for AML were poor, but the numbers are too small to make any definite conclusions.

References

Sep 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J KuerbitzW M Crist
Apr 1, 1991·British Journal of Haematology·M PhillipsJ Chessells
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C P SteuberT J Vietti
Jan 1, 1984·Medical and Pediatric Oncology·E Morgan
Apr 1, 1994·The Journal of Pediatrics·C H Pui, W M Crist
Apr 8, 1961·British Medical Journal·W M Brown, R Doll

❮ Previous
Next ❯

Citations

Dec 3, 2014·Blood Reviews·L ZhangC Metayer
Apr 8, 2006·Pediatric Blood & Cancer·Ronald M TanAllen E J Yeoh
May 21, 1998·Pediatric Hematology and Oncology·B S MenonN Jackson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.